01477.HK
Ocumension Therapeutics
HKSE · Healthcare · Biotechnology · CN
HKD 4.79
+3.90%Year over year
Reported trailing growth
- Revenue
- +71.8%
- EBITDA
- +117.3%
- EBIT
- +55.8%
- EPS
- +53.5%
- Free cash flow
- -40.7%
- Operating cash flow
- +92.0%
Forward estimates
Based on analyst estimates
- Revenue
- -30.0%
- EBITDA
- +425.8%
- EPS
- +126.5%
Three-year CAGR
- Revenue
- +71.7%
- EBITDA
- +90.7%
- EBIT
- +47.7%
- Net income
- +40.8%
- EPS
- +48.7%
- Free cash flow
- +12.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026